Alzheimer's disease drug development pipeline: 2024

Alzheimer s & Dementia Translational Research & Clinical Interventions, Journal Year: 2024, Volume and Issue: 10(2)

Published: April 1, 2024

New therapies to prevent or delay the onset of symptoms, slow progression, improve cognitive and behavioral symptoms Alzheimer's disease (AD) are needed.

Language: Английский

---

The neuropathobiology of multiple sclerosis

Nature reviews. Neuroscience, Journal Year: 2024, Volume and Issue: 25(7), P. 493 - 513

Published: May 24, 2024

Language: Английский

---

Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: June 6, 2024

Abstract Given the marginal penetration of most drugs across blood-brain barrier, efficacy various agents remains limited for glioblastoma (GBM). Here we employ low-intensity pulsed ultrasound (LIPU) and intravenously administered microbubbles (MB) to open barrier increase concentration liposomal doxorubicin PD-1 blocking antibodies (aPD-1). We report results on a cohort 4 GBM patients preclinical models treated with this approach. LIPU/MB increases by 2-fold 3.9-fold in human murine brains two days after sonication, respectively. Similarly, LIPU/MB-mediated disruption leads 6-fold aPD-1 concentrations peritumoral brain regions from pembrolizumab, Doxorubicin delivered upregulate major histocompatibility complex (MHC) class I II tumor cells. Increased achieved elicit IFN-γ MHC expression microglia macrophages. long-term survival glioma-bearing mice, which rely myeloid cells lymphocytes their efficacy. Overall, translational study supports utility potentiate antitumoral activities GBM.

Language: Английский

---

Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy

Protein & Cell, Journal Year: 2024, Volume and Issue: unknown

Published: May 11, 2024

Abstract Alzheimer’s disease (AD), the leading cause of dementia, is characterized by accumulation amyloid plaques and neurofibrillary tangles in brain. This condition casts a significant shadow on global health due to its complex multifactorial nature. In addition genetic predispositions, development AD influenced myriad risk factors, including aging, systemic inflammation, chronic conditions, lifestyle, environmental exposures. Recent advancements understanding pathophysiology are paving way for enhanced diagnostic techniques, improved assessment, potentially effective prevention strategies. These discoveries crucial quest unravel complexities AD, offering beacon hope management treatment options millions affected this debilitating disease.

Language: Английский

---

Focused ultrasound gene delivery for the treatment of neurological disorders

Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(3), P. 263 - 277

Published: Jan. 11, 2024

Language: Английский

---

Emerging Wearable Acoustic Sensing Technologies

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Sound signals not only serve as the primary communication medium but also find application in fields such medical diagnosis and fault detection. With public healthcare resources increasingly under pressure, challenges faced by disabled individuals on a daily basis, solutions that facilitate low-cost private hold considerable promise. Acoustic methods have been widely studied because of their lower technical complexity compared to other solutions, well high safety threshold human body acoustic energy. Furthermore, with recent development artificial intelligence technology applied speech recognition, recognition devices, systems capable assisting interacting scenes are constantly being updated. This review meticulously summarizes sensing mechanisms, materials, structural design, multidisciplinary applications wearable devices health human-computer interaction. Further, advantages disadvantages different approaches used flexible various examined. Finally, current roadmap for future research analyzed based existing progress achieve more comprehensive personalized healthcare.

Language: Английский

---

Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease

The Lancet Neurology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00570 - e00570

Published: March 1, 2025

Language: Английский

---

Exploiting the mechanical effects of ultrasound for noninvasive therapy

Science, Journal Year: 2024, Volume and Issue: 385(6714)

Published: Sept. 12, 2024

Focused ultrasound is a platform technology capable of eliciting wide range biological responses with high spatial precision deep within the body. Although focused already in clinical use for focal thermal ablation tissue, there has been recent growth development and translation ultrasound-mediated nonthermal therapies. These approaches exploit physical forces to produce dependent on exposure conditions. This review discusses advances four application areas that have seen particular immense potential: brain drug delivery, neuromodulation, tissue destruction, endogenous immune system activation. Owing maturation transcranial technology, major target organ; however, indications outside are also discussed.

Language: Английский

---

Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

CNS Drugs, Journal Year: 2024, Volume and Issue: 38(8), P. 613 - 624

Published: June 27, 2024

Alzheimer's disease (AD) is a complex multifaceted disease. Recently approved anti-amyloid monoclonal antibodies slow progression by approximately 30%, and combination therapy appears necessary to prevent the onset of AD or produce greater slowing cognitive functional decline. Combination therapies may address core features, non-specific co-pathology commonly occurring in patients with (e.g., inflammation), non-AD pathologies that co-occur α-synuclein). be advanced through co-development more than one new molecular entity add-on strategies including an agent plus entity. Addressing currently urgent since on included clinical trials for experimental agents. Phase 1 information must generated each drug development. 2 3 contrast entity, as standard care, combination. More development programs modified combinatorial designs are required two entities. Biomarkers markedly affected antibodies, these effects anticipated trials. Examining target engagement biomarkers comparing magnitude sequence biomarker changes those receiving therapy, compared monotherapy, informative. Using network-based medicine approaches, computational identify rational combinations using effect network mapping.

Language: Английский

---